The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Bevacizumab Biosimilars Market Expected To Reach Based On Its 2026 Value?
The bevacizumab biosimilars market size has experienced robust growth in recent years. It is anticipated to expand from $1.64 billion in 2025 to $1.77 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.5%. Historically, the growth in this market can be ascribed to elements such as the patent expiry of reference bevacizumab, an increase in cancer prevalence, the rising demand for cost-effective biologics, government incentives for biosimilars, and ongoing advancements in recombinant DNA technology.
The bevacizumab biosimilars market is projected to experience substantial expansion in the coming years, reaching a valuation of $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is primarily attributed to factors such as a rise in biosimilar approvals, the broadening of presence in emerging markets, the incorporation of AI into drug development processes, a growing inclination towards outpatient oncology treatment, and strategic alliances among pharmaceutical firms. Key trends anticipated during the same period encompass a heightened uptake of biosimilars in oncology, the availability of more economical treatment options, an increase in regulatory authorizations for biosimilar products, the expansion of both hospital and retail pharmacy infrastructures, and the proliferation of specialized cancer treatment facilities.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp
What Leading Drivers Are Supporting The Bevacizumab Biosimilars Market Expansion?
The increasing incidence of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market moving forward. Cancer incidence refers to the count of new cancer diagnoses observed in a specific demographic over a defined duration. Bevacizumab is a biologic agent that inhibits tumor angiogenesis, potentially leading to tumor shrinkage and suppressed growth, and it exhibits comparable effectiveness and safety to reference biologics when treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in October 2025, according to the NHS England, a UK-based government department, there were 354,820 new cancer diagnoses in England in 2023, which represents 8,605 more than in 2022. Therefore, the rising prevalence of cancer cases acts as a significant impetus for the bevacizumab biosimilars market.
What Segment Categories Shape The Bevacizumab Biosimilars Market Segment Landscape?
The bevacizumab biosimilars market covered in this report is segmented –
1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
What Trends Are Shaping The Future Of The Bevacizumab Biosimilars Market?
Major companies operating in the bevacizumab biosimilars market are concentrating on technological progress, such as next-generation indication-expanded formulations, to address the increasing need for more adaptable and cost-effective biologic treatments across oncology and non-oncology indications. These advanced formulations allow the core bevacizumab antibody to be used in new ways or for new conditions, permitting non-oncologic applications (e.g., ophthalmology) or simpler patient dosing, all while retaining the same VEGF-neutralizing action that traditional intravenous bevacizumab uses. For instance, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, introduced Versavo (bevacizumab) in the UK. This product is a premium biosimilar of Avastin (bevacizumab) developed for oncology treatments, making therapies for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more affordable for a wider patient base. Versavo is supplied in 100 mg and 400 mg single-use vials, consistent with standard bevacizumab dosing, and provides a biosimilar cost advantage that helps lessen the financial strain on healthcare systems and patients who depend on anti-VEGF therapy.
Who Are The Companies Operating Across The Bevacizumab Biosimilars Market Value Chain?
Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA
Get The Full Bevacizumab Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
Which Region Accounts For The Largest Portion Of The Bevacizumab Biosimilars Market?
North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Bevacizumab Biosimilars Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company
Bevacizumab Biosimilars Market Report 2026
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
Adalimumab Infliximab And Etanercept Biosimilars Market 2026
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model